Jordan Elm to Treatment Outcome
This is a "connection" page, showing publications Jordan Elm has written about Treatment Outcome.
Connection Strength
0.470
-
Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke. 2017 07; 48(7):2007-2012.
Score: 0.063
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.043
-
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2022 08; 17(7):806-809.
Score: 0.021
-
The Utility of Domain-Specific End Points in Acute Stroke Trials. Stroke. 2021 03; 52(3):1154-1161.
Score: 0.020
-
Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia. 2021 03; 62(3):795-806.
Score: 0.020
-
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
Score: 0.020
-
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020 07; 51(7):2058-2065.
Score: 0.019
-
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.
Score: 0.019
-
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 03; 51(3):792-799.
Score: 0.019
-
Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 12 01; 76(12):1466-1473.
Score: 0.019
-
Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.
Score: 0.019
-
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
Score: 0.018
-
Factors Influencing Oral Intake Improvement and Feeding Tube Dependency in Patients with Poststroke Dysphagia. J Stroke Cerebrovasc Dis. 2019 Jun; 28(6):1421-1430.
Score: 0.018
-
BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018 Nov - Dec; 11(6):1276-1281.
Score: 0.017
-
Long-Term Outcomes in Patients Aged =70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018 06; 49(6):1457-1463.
Score: 0.017
-
Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017 Nov; 82(5):755-765.
Score: 0.016
-
Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. Stroke. 2015 Aug; 46(8):2238-43.
Score: 0.014
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.013
-
Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug; 21(1):43-51.
Score: 0.013
-
Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr; 20(2):193-201.
Score: 0.013
-
Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan; 45(1):281-3.
Score: 0.012
-
The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92.
Score: 0.012
-
Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S130-7.
Score: 0.012
-
Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
Score: 0.009